Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Core Viewpoint - Viking Therapeutics experienced a significant decline in share price, dropping over 43% after disappointing mid-stage trial results for its weight-loss pill VK2735, reflecting intense competition in the pharmaceutical industry for oral weight-loss drugs [1][3]. Company Summary - Viking Therapeutics' shares fell approximately 43% to just below $24, marking the largest single-day decline since its IPO in May 2015 and a 69.5% decrease from its 52-week high of $81.73 set in October 2024 [3][4]. - The stock plunge resulted in about $1.8 billion in losses, reducing the company's market capitalization by more than one-third to $2.8 billion [4]. Product Performance - VK2735 demonstrated an average weight loss of 12.2% after 13 weeks, compared to a 1.3% loss with a placebo [4]. - However, 28% of patients discontinued the trial due to gastrointestinal side effects, including nausea and vomiting [5]. Competitive Landscape - VK2735's weight-loss results were lower than those of competitors, such as Eli Lilly's orforglipron, which achieved a 12.4% weight loss over 72 weeks, and Novo Nordisk's oral Wegovy, which helped patients lose 15% of their body weight [6]. - Eli Lilly's shares also fell over 14% following the release of orforglipron trial data, marking its largest single-day loss since 2000, while Novo Nordisk's shares rose more than 7% [7]. Industry Context - Viking Therapeutics is positioning itself in the growing weight-loss medication market, developing both oral and injectable alternatives [8]. - The oral version of Novo Nordisk's Wegovy is under FDA review, with a decision expected by late 2025, while other weight-loss pill trials, such as Pfizer's danuglipron, have been abandoned due to safety concerns [8].